AKT1 and neoplasm: Tregs activate two important pathways in effector T cells: the PI3K/Akt/mTOR pathway, leading to their dysfunction and inactivation, and the NF-κB pathway, reducing their ability to produce proinflammatory cytokines and eliminate tumor cells.